Enanta Pharmaceuticals Inc (ENTA)

[Jake2234]

“Key secondary endpoints evaluating virologic effect were not met. No difference was observed between patients treated with EDP-235 and placebo in viral RNA decline or infectious viral load, likely due to the rapid viral decline in the placebo arm of this trial’s seropositive, standard risk population. “

Let’s see how long this management team can milk that $450M for.